In a report released today, Bill Kerr from TD Cowen maintained a Buy rating on Chewy (CHWY – Research Report), with a price target of $45.00.
CRISPR Therapeutics (NASDAQ:CRSP) received an upgrade in its stock rating by analysts at TD Cowen, changing from Sell to Hold, while maintaining a price target of $35.00. The revision in the rating ...
TD Cowen analyst Moshe Orenbuch maintained a Hold rating on Bread Financial Holdings (BFH – Research Report) today and set a price target of ...